Form 4: Nuvalent CSO Sells Shares, Receives New Equity Awards

Nuvalent's Chief Scientific Officer, Henry E. Pelish, sold shares to cover tax obligations and received new restricted stock units and stock options.

Summary

• Henry E. Pelish, Chief Scientific Officer of Nuvalent, Inc. (NUVL), reported multiple transactions involving the company's Class A Common Stock.
• Pelish sold a total of 5,160 shares of Class A Common Stock across several transactions on January 5, 2026, and January 6, 2026.
• The sales were executed at weighted average prices ranging from $96.06 to $98.52 per share.
• These sales were conducted under a Rule 10b5-1 sell-to-cover instruction letter, established on December 6, 2023, to meet tax withholding obligations from the vesting of prior equity awards.
• Following these sales, Pelish's direct beneficial ownership of Class A Common Stock was 65,888 shares.
• On January 7, 2026, Pelish acquired 17,500 shares of Class A Common Stock in the form of Restricted Stock Units (RSUs) at a price of $0.00.
• These RSUs will vest in three equal annual installments starting after January 7, 2026, contingent on continued service.
• Also on January 7, 2026, Pelish acquired 17,500 stock options (right to buy) with an exercise price of $106.82 and a price of $0.00 for the derivative security.
• These stock options have an expiration date of January 7, 2036, and will vest over four years in equal monthly installments following January 7, 2026, subject to continued service.
• After the acquisition of RSUs, Pelish's direct beneficial ownership of Class A Common Stock increased to 83,388 shares, and he directly beneficially owned 17,500 stock options.

Sentiment

Score: 5

Explanation: The filing reports routine insider transactions, including sales for tax purposes and new equity awards. These are standard events for executives and do not inherently indicate a positive or negative shift in company fundamentals or outlook.

Positives

• The Chief Scientific Officer received a significant grant of 17,500 Restricted Stock Units (RSUs) and 17,500 stock options, indicating continued long-term incentive and alignment with company performance.
• The new equity awards (RSUs and stock options) have vesting schedules tied to continued service, reinforcing management's commitment to the company's future.

Negatives

• The Chief Scientific Officer sold 5,160 shares of Class A Common Stock, which, while for tax purposes, represents a reduction in direct equity holdings.

Future Outlook

The Chief Scientific Officer's new equity awards (RSUs and stock options) are subject to multi-year vesting schedules, indicating a long-term commitment to the company's future performance and continued service through at least January 7, 2029, for RSUs and January 7, 2030, for stock options.

Management Comments

• The sale was effected pursuant to a durable Rule 10b5-1 sell-to-cover instruction letter entered into on December 6, 2023, to satisfy the reporting person's tax withholding obligations upon the vesting of previously granted equity awards.

Industry Context

This filing reflects routine executive compensation practices in the biotechnology or pharmaceutical industry, where equity awards like RSUs and stock options are common tools for aligning executive incentives with shareholder value and retaining key talent. The use of a Rule 10b5-1 plan for tax-related sales is also a standard practice for insiders to manage their equity holdings compliantly.

Corporate Governance

Stakeholder Impact

• Shareholders: The transactions represent a routine adjustment in an executive's equity holdings and compensation, with new awards aligning the CSO's interests with long-term shareholder value. The sales for tax purposes are a common occurrence and generally not indicative of a lack of confidence.
• Employees: The grant of new equity awards to a key executive like the Chief Scientific Officer can signal stability and continued investment in leadership, potentially boosting morale.

Next Steps

• The acquired Restricted Stock Units (RSUs) will vest in three equal annual installments following January 7, 2026.
• The acquired stock options will vest over four years in equal monthly installments following January 7, 2026.

Key Dates

Keywords

Nuvalent, NUVL, Insider Transaction, Form 4, Equity Awards, Stock Options, Restricted Stock Units, RSU, Executive Compensation, Rule 10b5-1 Plan